Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease.
A case-control analysis of hospital-based data was conducted to evaluate whether low-dose combination oral contraceptives (OCs) protect against pelvic inflammatory disease (PID). Other categories of combination OCs based on estrogen dose were also assessed. The results indicate no OC confers protection if taken for less than 12 months. In contrast, the education-adjusted relative risk (RR) estimates for continuous exposure of greater than or equal to 12 months for various categories of combination OCs based on estrogen dose all ranged from 0.2 to 0.4 with overlapping 95% confidence intervals (CIs); however, the adjusted RR for low-dose pills was not statistically significant (RR = 0.4, 95% CI: 0.2, 1.1). These data are consistent with the hypothesis that low-dose estrogen pills as well as higher dose estrogen OCs potentially protect against PID requiring hospitalization. Low-dose estrogen combination OCs deserve further study in relation to PID generally, and more particularly, in regard to specific microorganisms causing PID.
Panser
L A
LA
Department of Obstetrics and Gynecology, University of Minnesota Medical School, Minneapolis.
Phipps
W R
WR
D016022:Case-Control Studies; D003277:Contraceptives, Oral, Combined; D005260:Female; D006801:Humans; D000292:Pelvic Inflammatory Disease / Q000453:epidemiology / Q000517:prevention & control*; D012307:Risk Factors; D013997:Time Factors; D014481:United States
D003277:Contraceptives, Oral, Combined